Trials / Conditions / Chronic Phase Chronic Myeloid Leukemia

Chronic Phase Chronic Myeloid Leukemia

11 registered clinical trials studyying Chronic Phase Chronic Myeloid Leukemia — 1 currently recruiting.

Status	Trial	Sponsor	Phase
Terminated	Safety and Efficacy Evaluation of Bosutinib Plus Atezolizumab in Newly Diagnosed Chronic Leukemia Adult Patien NCT04793399	Fundacion Espanola para la Curacion de la Leucemia Mieloide Cronica	Phase 1 / Phase 2
Recruiting	Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or So NCT03934372	Incyte Biosciences International Sàrl	Phase 1 / Phase 2
Active Not Recruiting	Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors NCT03610971	H. Lee Moffitt Cancer Center and Research Institute	Phase 2
Completed	Determining Change in Cardiovascular and Metabolic Risks in Patients With Chronic Phase Chronic Myeloid Leukem NCT03045120	Bristol-Myers Squibb	—
Terminated	A Study Comparing Ponatinib and Nilotinib in Participants With Chronic Myeloid Leukemia NCT02627677	Ariad Pharmaceuticals	Phase 3
Completed	Open-Label Study Evaluating Dasatinib Therapy Discontinuation in Patients With Chronic Phase Chronic Myeloid L NCT01850004	Bristol-Myers Squibb	Phase 2
Completed	Addition of P1101 to Imatinib Treatment in Patients With Chronic Phase Chronic Myeloid Leukaemia Not Achieving NCT01933906	Arbeitsgemeinschaft medikamentoese Tumortherapie	Phase 1
Completed	Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-Leukemia NCT01914484	University Health Network, Toronto	Phase 1 / Phase 2
Completed	Ruxolitinib in Combination With Nilotinib in Chronic Myeloid Leukemia (CML) Patients NCT01702064	H. Lee Moffitt Cancer Center and Research Institute	Phase 1
Completed	Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patien NCT01660906	Bristol-Myers Squibb	Phase 4
Completed	Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Resp NCT01593254	Bristol-Myers Squibb	Phase 2